Compare Genuine Parts Company (GPC) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Genuine Parts Company vs Summit Therapeutics Inc — how do they compare? Genuine Parts Company trades at $127.02 (market cap $17.67B), while Summit Therapeutics Inc trades at $17.59 (market cap $13.71B). The key difference: Genuine Parts Company is the larger of the two by market cap, and Genuine Parts Company pays a 3.32% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Genuine Parts Company for 75 Days and Summit Therapeutics Inc for 16 Days on average.
| GPC | SMMT | |
|---|---|---|
Market Cap | $17.67B | $13.71B |
Volume | 1,079,458 | 6,173,057 |
Sector | Consumer Cyclical | Health |
52-Week High | $149.26 | $26.38 |
52-Week Low | $92.47 | $12.43 |
Typical Hold Time | 75 Days | 16 Days |
Enterprise Value | $23.76B | $13.04B |
Dividend Yield | 3.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GPC trades at $128.17, up 2.2% today, with a bullish technical signal and analyst consensus price target of $145.75. Recent earnings show mixed results with Q1 and Q2 beats but a Q4 miss, while profitability metrics like net income margin remain thin at 0.13%. The company's planned separation into automotive and industrial units by Q1 2027 is a key catalyst, supported by steady revenue growth to $24.3 billion in 2025.
The outlook is cautiously optimistic, with upside potential from the corporate split and dividend stability, but risks include low profitability margins and rising debt levels. Analyst sentiment leans positive with 10 buy ratings, though execution risks and economic sensitivity warrant monitoring.
Summit Therapeutics (SMMT) trades at $17.59, down 2.01% on the day, amid mixed earnings performance but strong analyst support with a consensus price target of $29.33. The stock shows a bullish technical signal from moving averages, with key support at $17 and resistance at $18. Recent news highlights a major $2 billion strategic investment from AstraZeneca and expanded clinical collaborations, boosting investor optimism despite current negative profitability metrics.
The outlook for SMMT is heavily driven by clinical progress and partnerships, offering significant upside if drug trials succeed, but carries high risk due to substantial losses, negative cash flow from operations, and reliance on positive trial outcomes. Investors should weigh the potential rewards against the company's current financial health and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
